Who are Moderate-Dose Cannabidiol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MediCabilis CBD Oil, Cannabidiol (CBD) Extract, Cannabidiol (CBD) Oil Capsules, MPL-001 (CBD: THC 25:1), Placebo Matched to Low-Dose Cannabidiol, Cesamet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/moderate-dose-cannabidiol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Moderate-Dose Cannabidiol — Competitive Intelligence Brief

Moderate-Dose Cannabidiol (Moderate-Dose Cannabidiol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabinoid. Area: Neurology, Psychiatry, Immunology.

phase 3 Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor Neurology, Psychiatry, Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Moderate-Dose Cannabidiol (Moderate-Dose Cannabidiol) — Wayne State University. Cannabidiol modulates endocannabinoid signaling and multiple receptor pathways to produce anti-inflammatory, anxiolytic, and neuroprotective effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Moderate-Dose Cannabidiol TARGET	Moderate-Dose Cannabidiol	Wayne State University	phase 3	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Cannabidiol (CBD) Extract	Cannabidiol (CBD) Extract	Milton S. Hershey Medical Center	phase 3	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Cannabidiol (CBD) Oil Capsules	Cannabidiol (CBD) Oil Capsules	McMaster University	phase 3	Phytocannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multi-target)
MPL-001 (CBD: THC 25:1)	MPL-001 (CBD: THC 25:1)	McMaster University	phase 3	Cannabinoid combination	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Placebo Matched to Low-Dose Cannabidiol	Placebo Matched to Low-Dose Cannabidiol	Wayne State University	phase 3	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
Cesamet	NABILONE	Bausch Health	marketed	Cannabinoid [EPC]	Cannabinoid receptor 1	1985-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabinoid class)

Wayne State University · 3 drugs in this class
Hôpital le Vinatier · 1 drug in this class
Montefiore Medical Center · 1 drug in this class
OMNI Medical Services, LLC · 1 drug in this class
Gold Coast Hospital and Health Service · 1 drug in this class
Stero Biotechs Ltd. · 1 drug in this class
University of California, San Diego · 1 drug in this class
University of Connecticut · 1 drug in this class
Staci Gruber, Ph.D. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Moderate-Dose Cannabidiol — Competitive Intelligence Brief. https://druglandscape.com/ci/moderate-dose-cannabidiol. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab